Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.33 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 2/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26310194 | 0.91 | KDR (0.41) | KDRBRAFMAPKAPK2 | |
| SCHEMBL23999942 | 0.87 | MAPKAPK2 (0.34) | SIRT2SIRT1TNFMAPKAPK2 | |
| SCHEMBL23999524 | 0.85 | KDR (0.34) | KDRMAPKAPK2 | |
| SCHEMBL30180305 | 0.83 | KDR (0.40) | KDRTNFMAPK10MAPKAPK2 | |
| SCHEMBL23999478 | 0.83 | KDR (0.40) | KDRTNFMAPK10MAPKAPK2 | |
| SCHEMBL25826379 | 0.81 | KDR (0.35) | KDRAURKATLR8TLR7TLR9 | |
| SCHEMBL23999907 | 0.78 | MAPKAPK2 (0.42) | KDRMAPKAPK2 | |
| SCHEMBL23999518 | 0.76 | MAPKAPK2 (0.47) | MAPKAPK2 | |
| SCHEMBL30180637 | 0.76 | KDR (0.45) | KDRAURKAMAPKAPK2 | |
| SCHEMBL23999674 | 0.76 | KDR (0.45) | KDRAURKAMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | KDR 3433/4885PORCN 3819/4885AURKA 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.